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A direct comparison of effect sizes from the clinical global
impression-improvement scale to effect sizes from other rating
scales in controlled trials of adult social anxiety disordery
Dawson W. Hedges*, Bruce L. Brown and David A. Shwalb
Department of Psychology and the Neuroscience Center, Brigham Young University, Provo, UT, USA

Objective The clinical global impression-improvement scale (CGI-I) is used to monitor treatment outcome in mental disorders. To better
understand the properties of the CGI-I scale in social anxiety disorder, effects sizes from the CGI-I scale were compared to comparably
calculated effect sizes from other rating scales obtained from double-blind, placebo-controlled trials of selective-serotonin reuptake inhibitors
in social anxiety disorder. From peer-reviewed, double-blind, placebo-controlled studies evaluating selective serotonin reuptake inhibitors in
social anxiety disorder, we extracted CGI-I data and scores from other assessment scales of severity and function. Using calculations that
enabled direct comparisons, effect sizes for the binarily reported CGI-I scores were compared to effect sizes from the quantitative scales.
Results Effect sizes for the binary CGI-I scale were statistically indistinguishable from effect sizes obtained from the other scales, with the
exception of the social avoidance and distress scale.
Conclusions The CGI-I scale is an appropriate method of assessing clinical change in trials of social anxiety disorder. Copyright # 2008
John Wiley & Sons, Ltd.
key words — clinical global impression-improvement scale; social anxiety disorder; social phobia; assessment scales

INTRODUCTION
Developed as part of the Population Reference
Bureau’s collaborative studies on schizophrenia, the
clinical global impression (CGI) scale is designed to
determine the severity of illness in both children and
adults (Guy, 1976) and includes three subscales: the
CGI-severity scale, the CGI-efficacy index, and the
CGI-improvement (CGI-I) scale (Guy, 1976). In
particular, results from the CGI-I scale are often
reported in a binary fashion; that is, subjects are
assessed as either being responders or non-responders,
with responders defined as a rating of either very much
improved or much improved. However, the CGI-I scale
also can be reported quantitatively as numerical values
ranging from 1 to 7.
Since its introduction, the CGI-I scale has been used
as a clinical rating scale to measure treatment response
in clinical trials involving several psychiatric disorders
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including but by no means limited to schizophrenia,
generalized anxiety disorder, attention-deficit, hyperactivity disorder, social anxiety disorder, generalized
anxiety disorder, and depression (Gattaz et al., 2004;
Lader et al., 2004; Silva et al., 2004; Steiner et al.,
2005; e.g., Gorman et al., 2002). Not only is the CGI-I
scale used extensively in clinical trials, its use as a
clinical outcome measure is reasonably well accepted.
For example, in their analysis of the CGI-severity and
CGI-I scales, Leon and his colleagues (1993)
concluded that the use of the CGI-severity and CGII scales is justified in clinical trials and appears to
capture important aspects of the patients’ condition.
Despite its generalized use and acceptance in clinical
trials of psychotropic drugs, there are, nevertheless,
concerns about the CGI-I scale (Beneke and Rasmus,
1992). Few studies, for example, have rigorously
examined the psychometric properties of the CGI scale
(Guy, 2000), even though it is widely used as an
outcome measure in clinical trials. As such, additional
research on the strengths, weaknesses, and appropriate
use of the CGI-I scale is needed, particularly, in the
clinical-trial settings in which it is most frequently
used. One method to further investigate the properties
Received 21 March 2008
Accepted 26 September 2008

10991077, 2009, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.989 by Brigham Young University, Wiley Online Library on [20/10/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

human psychopharmacology

d. w. hedges

of the CGI-I scale is to compare the results obtained
from the CGI-I scale with those obtained from other
clinical rating scales during randomized, placebocontrolled trials, in which clinical rating scales
themselves are administered in a double-blind fashion.
The use of multiple rating scales including the CGI-I
scale in many clinical trials enables a direct
comparison between results obtained by use of the
CGI-I scale and other clinical rating scales. In this
analysis, double-blind, placebo-controlled trials of
selective serotonin reuptake inhibitors in social anxiety
disorder were evaluated to compare effect sizes
determined from the binarily reported CGI-I scale to
effect sizes obtained from other clinical rating scales in
an effort to better understand the psychometric
properties of the CGI-I scale. We limited this analysis
to only trials of social anxiety disorder to avoid
introducing the potential confound whereby the
psychometric properties of the CGI-I may differ from
disorder to disorder, much like clinical drug trials
evaluate the effects of a drug in only one disorder. As
an aid to making the interpretation of these findings as
simple as possible, methods of effect-size calculation
enabling a direct comparison between binary CGI-I
data and the quantitative data from the other rating
scales were used.
METHODS
Using the search terms social phobia and social anxiety
disorder combined sequentially with the generic names
of the selective reuptake inhibitors citalopram,
escitalopram, fluoxetine, fluvoxamine, paroxetine,
and sertraline in the electronic search engines Medline
(via PubMed) and PsychInfo, we searched for peerreviewed papers reporting the results of randomized,
placebo-controlled trials of selective serotonin
reuptake inhibitors in social anxiety disorder. We also
reviewed the text and reference lists of relevant papers
and review papers to find any additional papers. We
further selected only those studies that reported results
from the binary CGI-I scale and at least one other rating
scale assessing either social anxiety disorder severity
or function. We further restricted the analysis to rating
scales that directly assess social anxiety disorder. That
is, we did not include general measures of anxiety or
depression. Furthermore, we limited the analysis to
selective serotonin reuptake inhibitors to minimize
confounding due to different adverse-effect profiles
from drugs of different classes.
To maintain consistent methodology and diminish
bias as much as possible, case studies, case series, and
unblinded trials were excluded. The studies in which
Copyright # 2008 John Wiley & Sons, Ltd.
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there were not only placebo and active-drug arms but
also psychotherapy or the combination of drug and
psychotherapy arms, or both, only results from the
placebo and active-drug arms were used. Similarly,
only the double-blind, placebo-controlled parts of trials
that included an unblinded component were analyzed.
Data for the drug used, rating scales, differences
between baseline and endpoint scores, and either
standard deviations or standard errors for the differences between baseline and endpoint data or scores
from each study were recorded. We used only data
supplied in the study; we did not use estimates of
crucial data in the analyses. Accordingly, we report
findings for only those studies containing complete
data for at least the CGI-I and one other rating scale.
Because of their desirable distributional properties,
log-odds ratios are often used for calculating effect
sizes for binary data (Sprott, 1973). However, log-odds
ratios substantially amplify the effect sizes in
comparison with theta effect-size values for quantitative data based upon the standardized differences
between means. Since proportions are a special case of
means, a more direct comparison between binary and
quantitative data can be made by calculating the effect
size for binary data as a standardized difference
between proportions.
The basic formula we used for the standardized
difference between means for the quantitative rating
scales is
u ¼ X T sM X C
in which X T is the treatment mean difference between
baseline and endpoint scores, X C the placebo mean
difference between baseline and endpoint scores, and sM
is the pooled estimate of the standard deviation for the
difference scores. Because the binary CGI-I is a binary
indication of improvement versus no improvement, the
comparable formula for binary data is simply the
standardized difference between the proportion improved
in the treatment group and the proportion improved in the
control group:
u ¼ PT sP PC
in which PT is the treatment proportion improved, Pc the
placebo proportion improved, and sP is the pooled estimate
of the standard deviation of the proportion. This formula is
used to obtain an estimate of u, that is, effect size, which is
comparable to the effect sizes for fully quantitative data.

To convert the standardized difference between
means to the Hedges’ G, a measure that weights effect
sizes from the source studies according to the size of
the study, we multiplied by the J correction factor
(1  (3/(4  (degrees of freedom  1))), in which
Hum. Psychopharmacol Clin Exp 2009; 24: 35–40.
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degrees of freedom ¼ n  2) (Hedges and Olkin, 1985).
A random-effects model was used for all calculations
that pooled data from the source studies to compute a
summary effect size. Comprehensive meta-analysis
(2.0) (Biostat, Englewood, NJ) software was used for
computing effect sizes from individual studies and
when pooling data across studies to obtain summary
effect sizes. When possible, we calculated effect sizes
from intent-to-treat samples sizes, defined as the
number of subjects randomized regardless of whether
outcome data after randomization were available.
When intent-to-treat data were not available, we used
sample sizes from the last observation carried forward
pool, in which cases the sample sizes had the potential
to be smaller than the number randomized. When
intent to treat and last observation carried forward data
were not available, we used the number of subjects who
completed the trial.
In the identified studies reporting binary data for the
CGI-I scale, we calculated effect sizes from rating
scales that occurred in at least two studies and
compared the resulting effect size to the effect size
from the CGI-I scales obtained from only those studies
containing the comparison scale in question.

RESULTS
We initially identified 20 double-blind, placebocontrolled trials of selective serotonin reuptake
inhibitors in social anxiety disorder. Of these, 16
randomized, double-blind, placebo-controlled trials of
selective serotonin reuptake inhibitors (see Table 1)
reported data from the binary CGI-I scale and at least
one other rating scale for improvement by which to
compare the CGI-I scores (Stein et al., 1998;
Allgulander, 1999, Baldwin et al., 1999; Stein et al.,
1999; Van Ameringen et al., 2001; Kobak et al., 2002;
Liebowitz et al., 2002; Liebowitz et al., 2003;
Davidson et al., 2004a,b; Lader et al., 2004; Lepola
et al., 2004; Westenberg et al., 2004; Furmark et al.,
2005; Kasper et al., 2005; Asakura et al., 2007) and
were included in the meta-analysis. See Table 1 for a
summary of the source studies. The Q statistic, a
measure of variability of the source studies, was
significant for the binary CGI-I from all 16 studies,
indicating significant variation between source studies.
After eliminating the study (Allgulander, 1999) with
the most extreme binary CGI-I effect size from the
analysis, the Q statistic became nonsignificant,
indicating acceptable homogeneity among the remaining 15 studies, from which the analysis was done.
Likewise, Q statistics were calculated for the studies in
Copyright # 2008 John Wiley & Sons, Ltd.

Table 1. Source study characteristics
Clinical trial

N

Stein et al. (1998)
Allgulander (1999)
Baldwin et al. (1999)
Stein et al. (1999)
van Ameringen et al. (2001)
Kobak et al. (2002)
Liebowitz et al. (2002)a
Liebowitz et al. (2003)
Davidson et al. (2004a)

183
282
86
203
60
544
401
247

Davidson et al. (2004b)
Lader et al. (2004)b
Lader et al. (2004)b
Lepola et al. (2004)

183
982
330
370

Westenberg et al. (2004)

294

Furmark et al. (2005)
Kasper et al. (2005)
Asakura et al. (2007)

24
353

Drug
Paroxetine
Paroxetine
Paroxetine
Fluxoxamine
Sertraline
Fluoxetine
Paroxetine
Sertraline
Fluvoxamine
(controlled release)
Fluoxetine
Escitalopram
Paroxetine
Paroxetine
(controlled release)
Fluvoxamine
(controlled release)
Citalopram
Escitalopram

N ¼ number of subjects.
a
The Liebowitz et al. (2002) data were reported for three arms of the study
corresponding to three dose levels; for the purpose of the meta-analysis, the
effect sizes from each arm were averaged to obtain one overall effect size
from this study.
b
The Lader et al. (2004) data are from the same studies but the escitalopram
and paroxetine data are reported separately.

each individual rating-scale analysis. When the Q
statistic was significant, the most extreme study was
eliminated, which in all cases resulted in a nonsignificant Q statistic. Because not all studies reported
data on the same rating scales and because some rating
scales in the individual analyses resulted in significant
Q values, the number of source studies in the analyses
of the individual rating scales varied from a high of 6 to
a low of 2. Only nine studies reported sufficient data to
calculate effect sizes without having to estimate critical
data, and the results contain data from only these nine
studies (see Table 2). Most of the studies using the
Liebowitz social anxiety scale reported the total score.
Although Lepola et al. (2004) did not report total
scores for the Liebowitz social anxiety scale, effect
sizes were calculated from summed subscales. In the
case of Stein et al., 1999, we estimated values for the
Liebowitz social anxiety scale and for the brief social
phobia scale from graphs included in the paper.
As shown in Table 2, effect sizes from the binary
CGI-I scale did not significantly differ from effect sizes
obtained from the Liebowitz social anxiety scale, the
brief social phobia scale, the CGI-severity scale, the
Sheehan disability inventory-social scale, the Sheehan
disability inventory-work scale, the Sheehan disability
inventory-family scale, and the CGI-I scale in
quantitative form. Only the effect size from the social
Hum. Psychopharmacol Clin Exp 2009; 24: 35–40.
DOI: 10.1002/hup
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Table 2. Effect sizes for the binary CGI-Improvement scale compared to
other rating scales
Scale compared
LSAS
CGI-I
BSPS
CGI-I
SADS
CGI-I
CGI-S
CGI-I
SDI-S
CGI-I
SDI-W
CGI-I
SDI-F
CGI-I
CGI-Q
CGI-I

Combined effect size

t-test value

p-value

.4413
.4768
.3881
.3716
.3512
.5598
.5465
.5598
.3643
.5993
.4411
.5993
.3211
.5993
.4384
.3495

.4120

.6974

.1973

.8619

7.024

.0197

.2191

.8469

1.324

.4119

1.531

.3683

3.310

.1868

1.343

.2718

CGI-I ¼ clinical global impression-improvement scale (Guy, 1976).
LSAS ¼ Liebowitz social anxiety scale (Heimberg et al., 1999) (studies
used (n ¼ 6): Stein et al., 1998; Baldwin et al., 1999; Stein et al., 1999;
Kobak et al., 2002; Davidson et al., 2004a; Lepola et al., 2004).
BSPS ¼ brief social phobia scale (Davidson et al., 1997) (studies used
(n ¼ 3): Stein et al., 1999; Van Ameringen et al., 2001; Kobak et al., 2002).
SADS ¼ social avoidance and distress scale (Watson and Friend, 1969)
(studies used (n ¼ 3): Baldwin et al., 1999; Van Ameringen et al., 2001;
Lepola et al., 2004).
CGI-S ¼ clinical global impression-severity scale (Guy, 1976) (studies used
(n ¼ 3): Baldwin et al., 1999; Van Ameringen et al., 2001; Lepola et al.,
2004).
SDI-S ¼ Sheehan disability inventory-social (Sheehan, 1983) (studies used
(n ¼ 2): Baldwin et al., 1999; Lepola et al., 2004).
SDI-W ¼ Sheehan disability inventory-work (Sheehan, 1983) (studies used
(n ¼ 2): Baldwin et al., 1999; Lepola et al., 2004).
SDI-F ¼ Sheehan disability inventory-family (Sheehan, 1983) (studies used
(n ¼ 2): Baldwin et al., 1999; Lepola et al., 2004).
CGI-Q ¼ clinical global impression-improvement in quantitative form
(Guy, 1976) (studies used (n ¼ 4): Van Ameringen et al., 2001; Liebowitz
et al., 2003; Davidson et al., 2004a; Westenberg et al., 2004).
All Q tests were statistically nonsignificant, indicating no violation of
homogeneity.

avoidance and distress scale differed significantly from
the effect size obtained from the binary CGI-I scale.
DISCUSSION
One method of decreasing the chances of a type I error
occurring due to the use of multiple rating scales to
determine study outcome is to keep the number of
rating scales to a minimum (Leon, 2005). To do so,
rating scales should be chosen judiciously in order to
avoid the use of scales that themselves inadvertently
may contribute to type I and II errors. That is, rating
scales overestimating or underestimating the desired
clinical effects in a clinical trial weaken a study’s
credibility. As such, the relative merits of each rating
scale become crucial to study design. Unfortunately,

Copyright # 2008 John Wiley & Sons, Ltd.
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little information exists concerning the advantages and
disadvantages of different rating scales for social
phobia. The results reported herein suggest that in
clinical trials evaluating social anxiety disorder in
adults, the standardized mean difference between
proportions from the commonly used binary CGI-I
scale (Guy, 1976) are statistically indistinguishable
from effect sizes for the Liebowitz social anxiety scale
(Heimberg et al., 1999), the brief social phobia rating
scale (Davidson et al., 1997), the CGI-severity scale
(Guy, 1976), the three subscales of the Sheehan
disability inventory (social, work, and family) (Sheehan, 1983), and the CGI-I scale in quantitative form
(Guy, 1976). Of the eight scales analyzed, only effect
sizes from the social avoidance and distress scale
(Watson and Friend, 1969) differed significantly from
the binary CGI-I scale where the CGI-I had a larger
effect size than the social avoidance and distress scale
( p ¼ .0197). That is, effect sizes obtained from the
CGI-I binary scale were equivalent to both unrelated
scales (the Liebowitz social anxiety scale, the brief
social phobia rating scale, the Sheehan disability
inventory) and scales within the CGI family (CGIseverity, CGI-I in quantitative form). As such, the
binary CGI-I appears to be a reasonable method of
assessing clinical change in adult social anxiety
disorder yielding effect sizes of change statistically
identical to scales designed specifically to assess
response to treatment in social anxiety disorder such as
the Liebowitz social anxiety scale and the brief social
phobia rating scale. Further, it does not appear to
matter whether the results from the CGI-I are in binary
or quantitative form.
Effect sizes from the binary CGI-I scale were also
not significantly different from the three subscales of
the Sheehan disability inventory, which assess actual
social, work, and family function (Sheehan et al.,
1996).
Because there is no definitive standard by which to
determine response to treatment in social anxiety
disorder, the convergence between effect sizes
obtained from several different scales assessing clinical
change in social anxiety disorder suggests that the
scales are inherently measuring the same type of
improvement to the same degree.
Although it has been argued that that the task of
comparing subject’s global clinical condition at study
end to the subject’s state at the beginning of the clinical
trial becomes essentially a test of the rater’s memory,
which may be subject to error (Guy, 2000), the results
reported herein argue that the binary CGI-I is indeed an
effective method of assessing clinical change in a
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subject, even though the CGI-I is not specific for
detecting change in just social anxiety disorder.
Several limitations to this study require consideration. The overall number of source studies included
was relatively small and included only the use of
selective serotonin reuptake inhibitors in social anxiety
disorder. The possibility that drugs from other classes
may result in a discrepancy between the CGI-I scale
and the other scales used in the evaluated studies
require consideration. For example, adverse-effect
profiles from other drug class could potentially lower
estimations from the CGI-I scale, whereas other scales
that specifically evaluate features of social anxiety
disorder itself might not change as much. That is, it is
conceivable that the CGI-I could be more sensitive to
adverse effects than scales designed specifically for
features of social anxiety disorder. Nonetheless, if it
were the case that assessments of clinical improvement
were lowered because of a drug’s adverse-effect
profile, the CGI-I would still be assessing clinical
improvement consistent with other rating scales, but
the assessment would be contaminated by adverse
effects.
An additional limitation is that the current findings
were drawn only from clinical trials of social anxiety
disorder, leaving unaddressed questions about the
consistency of the CGI-I scale and other rating scales in
other disorders. The findings reported herein are of
limited generalizability to other illnesses and even to
other classes of psychotropic drugs. Only actual data
from clinical trials can determine whether assessment
using the binary CGI-I is consistent with rating scales
used to evaluate clinical response in other disorders. A
further potential concern is the propriety of comparing,
as we did, scales, such as the CGI-I scale, with other
scales designed to measure severity or impairment, or
comparing scales that assess global function with
scales that assess specific features of social anxiety
disorder. Regardless of the original purpose of the
scales, however, the scales compared in our analysis
had been used in the source studies to assess clinical
outcome, heightening the need to compare the
evaluations made with these potentially diverse scales
with each other to determine their properties under
clinical-trial conditions.
A major limitation of this study is that presumably
the different rating scales in each source study were
completed by the same rater; that is, the same person
completing the CGI-I also would have completed, for
example, the Liebowitz social anxiety scale. If the
CGI-I was completed after the completion of another
scale, the rater would have completed the CGI-I

Copyright # 2008 John Wiley & Sons, Ltd.
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scale having access to the information obtained from
the previously completed scales, a process that could
inflate the correlation between effect sizes for the two
scales. Inflated correlation between the CGI-I scale and
other scales would not be a problem when the CGI-I
was completed before the other scales. Because the
order of scale completion is unclear from the source
studies, inflated correlation between effect sizes could
have contributed to our results.
Another major limitation of our study is the small
number of source studies used in our analysis. Overall,
only 16 studies met inclusion criteria. Of these, only
nine reported sufficient data to calculate effect sizes
without having to estimate critical variables. Because
source studies varied in the rating scales used, none of
our analyses used data from more than six studies, and
some were based on as few as two studies, rendering
the results susceptible to data from additional studies.
In fact, in the one case in which there was a significant
difference between the CGI-I scale and the comparison
scale (the social avoidance and distress scale), the
number of source studies was only three. Were more
studies evaluated, it is possible that the significant
difference would disappear. However, the results
reported in this paper are based upon actual reported
numbers in the source studies and not on estimations in
cases of missing data. While the method of using only
reported data and not estimates in this particular study
limits the number of source studies contributing to the
overall results, it reduces the potential for error in the
final results as well.
From the point of view of number of source studies
contributing to a meta-analysis, the most robust results
from this study are for the Liebowitz social anxiety
scale, in which case, there were six source studies
contributing to the overall effect sizes reflecting the
widespread use of the Liebowitz social anxiety scale as
an outcome measure in clinical trials of social anxiety
disorder (Stein et al., 2004). In this case, there was no
difference in the effect sizes obtained from the binary
CGI-I and the Liebowitz social anxiety scale,
suggesting that the CGI-I performs as well in social
anxiety disorder as the commonly used Liebowitz
social anxiety scale and highlighting the value of the
binary CGI-I as a tool in assessing clinical change in
social anxiety disorder.
CONCLUSION
The results from this analysis comparing standardized
mean differences between proportions obtained from
the binary CGI-I scale to effect sizes from other rating
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scales commonly used in clinical trials of social
anxiety disorder when calculated by directly comparable methods suggest that effect sizes do not
statistically differ between the binary CGI-I scale
and the Liebowitz social anxiety scale, the brief social
phobia scale, the Sheehan disability inventory, the
CGI0-severity scales, and the quantitative CGI-I scale.
Only the social avoidance and distress scale showed a
statistically significant difference in effect sizes
compared to the CGI-I scale, a discrepancy that may
well have been due to the small number of source
studies used in that analysis. Based on these findings, it
appears that use of the CGI-I scale is an appropriate
method of determining clinical change in trials of
social anxiety disorder. Additional research is needed
to define the relative advantages and disadvantages of
rating scales including the CGI-I scale not only for
trials of social anxiety disorder but other psychiatric
disorders as well.
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